Improving Strategies in the Development of Protein-Downregulation-Based Antiandrogens

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The androgen receptor (AR) pathway is critical in prostate cancer (PCa) and remains active in castration-resistant prostate cancer (CRPC).
• Current antiandrogen therapies face resistance due to mechanisms like AR mutations, splice variants, and overexpression.
• Developing novel antiandrogens is essential to overcome treatment resistance in advanced PCa.

Purpose of the Study:

• To review current strategies for downregulating the androgen receptor (AR) protein.
• To explore novel therapeutic approaches for overcoming antiandrogen drug resistance in prostate cancer.
• To provide insights for the development of next-generation antiandrogen drugs.

Main Methods:

• Literature review of AR downregulation strategies.
• Analysis of emerging antiandrogen therapies targeting AR.
• Summary of mechanisms to overcome AR-mediated resistance.

Main Results:

• Several strategies for AR downregulation are emerging, including G-quadruplex stabilizers, ROR-γ inhibitors, AR-targeting proteolysis targeting chimeras (PROTACs), and selective AR degraders (SARDs).
• These novel approaches demonstrate potential in overcoming resistance mechanisms prevalent in CRPC.
• Downregulating AR at the mRNA or protein level offers promising avenues for new antiandrogen drug development.

Conclusions:

• Targeting AR downregulation represents a promising strategy for developing novel antiandrogen therapies.
• Emerging AR-targeting agents like PROTACs and SARDs show potential to overcome resistance in CRPC.
• Further research into AR downregulation mechanisms can lead to more effective treatments for advanced prostate cancer.